Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
DURHAM, N.C., May 02, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 8:40 a.m. ET at the InterContinental Boston Hotel.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
